Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature

Abstract

Psoriasis management may be challenging, particularly for moderate-to-severe forms of the disease. Indeed, conventional systemic treatments are often avoided for contraindications or the risk of adverse events as well as phototherapy is often limited by logistic concerns. Despite the development of biological drugs and small molecules revolutionized the treatment options showing promising results in terms of safety and effectiveness, some limitations remain. Thus, there is still a need for new therapies that are always welcome in order to tailor the treatment to the patient and to have a higher level of performance, especially in order to maintain long-term effectiveness. In this scenario, deucravacitinib, an oral small molecule which selectively inhibits Tyrosine Kinase 2, may represent a promising weapon in psoriasis management. The aim of our manuscript is to review the current knowledge on the efficacy and safety of deucravacitinib for the management of psoriasis.

Assessment of the anti-psoriasis effect of Scrophularia deserti methanolic extract in mice model

“…Psoriasis is a skin-based disease with immune and inflammatory-mediated reasons characterized by unequal keratinocyte hyperproliferation, giving rise to epidermis inflammatory response, flaking, and thickening [1]. Affected skin may be degenerated to silver, white, or red with scaly plaques [2]. Itching, scaling, burning, erythema, and bleeding are the most routine psoriasis symptoms [3].…”

Mechanistic Investigation of WWOX Function in NF-kB-Induced Skin Inflammation in Psoriasis

“…Therefore, JAK inhibitors have the potential to offer an oral alternative to the currently available systemic therapeutics, including methotrexate, apremilast, and biologics [ 10 ]. Deucravacitinib is the first oral selective tyrosine kinase 2 (TYK2) inhibitor responsible for the signaling of IL-23 and other cytokines involved in the pathogenesis of psoriasis [ 11 , 12 ]. JAK 1/3 inhibitor tofacitinib and the selective JAK1 inhibitor upadacitinib have been also approved in psoriatic arthritis [ 13 ].…”